Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Precision Cell Immunotherapy + Chemotherapy in Advanced Lung Cancer
NCT02873416Phase 2Unknown
- Sponsor
- Ningbo Cancer Hospital
- Start
- Aug 2016
- Primary completion
- Mar 2018
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Precision Cell Immunotherapy in lung cancer (2 arms), sponsored by Ningbo Cancer Hospital. Primary endpoints: Overall Survival at 2 years and Progression-Free Survival at 2 years. Status: unknown.
02
Drugs
Precision Cell Immunotherapy
03
Conditions
lung cancer
Beyond the preview
Go deeper on NCT02873416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02873416.